Sells the only FDA-approved pill for a rare hormone disorder called Cushing's syndrome, distributed through a tightly controlled prescriber network.
At a glance
- Depends onMidstream position: 3 outgoing, 3 incoming connections
- Scale
Sells the only FDA-approved pill for a rare hormone disorder called Cushing's syndrome, distributed through a tightly controlled prescriber network.
Corcept Therapeutics sells a single drug, Korlym, which works by blocking the body's cortisol receptors rather than lowering cortisol itself — a distinction specific enough that the FDA approved it as the only treatment of its kind for the blood sugar complications of Cushing's syndrome. Because blocking those receptors removes the body's normal signal for detecting adrenal distress, the FDA requires every prescribing endocrinologist to complete individual certification training and enroll each patient in a registry before a prescription can be filled, so every sale flows through a compliance system that also functions as the distribution channel. That certification cannot be done in bulk or delegated, which means the pool of doctors legally able to write the prescription can only grow one physician at a time no matter how much the company spends on sales. The whole structure depends on a single molecule: mifepristone is also used in medication abortion, so its manufacturing is regulated by both the FDA and the DEA simultaneously, and if a DEA scheduling change further restricted who could produce it, there is no other approved cortisol receptor antagonist that could step in.
How does this company make money?
The company earns revenue each time a Korlym prescription is filled through a specialty pharmacy. Because Korlym is a high-cost drug for a rare condition, whether a patient can actually receive it depends heavily on whether their insurance approves reimbursement and whether the company's copay assistance program covers what insurance does not.
What makes this company hard to replace?
Endocrinologists who prescribe Korlym have already gone through the specific FDA REMS certification required for this drug — starting over with a different treatment would mean learning a new protocol without any equivalent structure in place. Patients already enrolled in the Korlym registry cannot transfer that enrollment to another drug. Most importantly, there is no other approved cortisol receptor antagonist for Cushing's syndrome to switch to, so for most patients there is simply no alternative path.
What limits this company?
Each endocrinologist must personally complete the FDA REMS training and keep their certification current before they can write a single Korlym prescription. That training cannot be done in a group or delegated to someone else, so the number of doctors who can prescribe the drug grows one physician at a time — no matter how many patients need it or how much money is spent on outreach.
What does this company depend on?
The company cannot operate without mifepristone active pharmaceutical ingredient from specialized contract manufacturers, the FDA REMS program infrastructure for prescriber certification, a network of endocrinologists trained in cortisol receptor antagonism, specialty pharmacy distribution channels equipped to handle restricted-access medications, and patent protection on cortisol receptor modulation methods.
Who depends on this company?
Patients with endogenous Cushing's syndrome who have already had surgery and still need treatment would lose their only FDA-approved option for controlling blood sugar if Korlym disappeared. Specialty endocrinology practices that rely on cortisol receptor blockade as the next step when surgery fails would have no approved replacement to offer. Academic medical centers that use selective cortisol modulators in research would also lose access to the tool.
How does this company scale?
The digital systems that handle REMS-compliant prescription processing and patient registry management can handle more patients without much added cost as volume grows. What does not scale the same way is the prescriber side: because each endocrinologist must individually complete FDA training and keep their certification active, the pool of doctors who can legally write the prescription can only grow one physician at a time.
What external forces can significantly affect this company?
Medicare Part D coverage decisions can determine whether a high-cost rare disease therapy like Korlym gets reimbursed at all, which directly affects how many patients can afford it. The DEA's ongoing authority over mifepristone — because of its use in pregnancy termination — means a scheduling change could disrupt manufacturing at any time. Selling the drug outside the United States would require a completely separate clinical development process under the European Medicines Agency, since the existing FDA approval does not carry over.
Where is this company structurally vulnerable?
Mifepristone is also the main drug used in medication abortion, which means the DEA regulates it alongside the FDA. Only a narrow set of manufacturing facilities are equipped to meet both agencies' requirements at once. If the DEA changed mifepristone's scheduling status in a way that further restricted commercial production, the supply of Korlym could be cut off — and there is no other approved cortisol receptor antagonist that could replace it.
Sign in to view price data.
Sign inStructural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph